• Event Type: Earnings Conference Call for Q1 FY27 results discussion and investor interaction
  • Date and Time: August 12, 2026 (specific time not mentioned in the transcript)
  • Purpose: Discussion of unaudited financial results for the quarter ended June 30, 2026, business highlights, and strategic updates
  • Management Participants: Dr. Haribabu Bodepudi (Managing Director & Group CEO), Mr. Rajaram Narayanan (Executive Director and CEO, Animal Health), Mr. Ramakant Singani (Chief Financial Officer), Mr. Abhishek Singhal (Moderator/IR)
  • Availability of Materials: The earnings call transcript will be available on the company's website within a week's time at https://viyash.com/financial
  • UPSI Statement: The company indicated that the discussion may be forward-looking in nature and must be viewed in relation to the risks pertaining to the business

Financial Period Discussed: Q1 FY27 (quarter ended June 30, 2026)

Financial Highlights:

  • Revenue from operations: ₹946 crores, grown by 20% year-on-year
  • EBITDA: ₹205 crores, grown by 59% year-on-year
  • EBITDA margin: 21.6%, expanding by 530 basis points over last year
  • Profit after tax: ₹79 crores, more than doubled year-on-year
  • Gross margin: 54.1% compared with 51.9% in Q1 FY26
  • Profit before tax: ₹112 crores, increased by 132% year-on-year
  • Finance costs: ₹12.5 crores, declined from ₹20.4 crores in Q1 FY26
  • Net debt: ₹86 crores, net debt to EBITDA at 0.1x

Strategic Updates and Forward-looking Statements:

  • Integration of merged entities is complete
  • Signed SPA for Bio For Life acquisition in Italy, expected to close in next few months
  • Focus on companion Animal Health as number one strategic growth area for next 5 years
  • Investing in R&D and manufacturing expansion for companion animal products
  • Target to achieve billion dollar revenue by 2032
  • Planning to expand field force and product portfolio in domestic market
  • Focusing on first-to-file opportunities in Human Formulations with backward integration
  • API business expected to have strong recovery in current quarter

Additional Notes Section

  • The document includes the full earnings call transcript with Q&A session
  • No financial data attachments were mentioned in the announcement
  • The company granted ₹1.3 crores employee stock options, representing 2.8% of post-amalgamation paid-up share capital, resulting in incremental expense of ₹19 crores for the quarter
  • ESOP cost for FY27 is expected to be about ₹150 crores, reducing to ₹25-30 crores in FY28